Table 3.
Lung adenocarcinoma risk associated with the number of high-risk genotypes of FANCD2 and FANCI in male and female lung adenocarcinoma patients-Joint effect of component genes in the FA UB complex
| Genotype of | No. cases (%) | No. controls (%) | aOR (95 % CI)a | P for trend | |
|---|---|---|---|---|---|
| FANCD2 b | FANCI b | ||||
| Male lung adenocarcinoma patients | |||||
| AA | CC | 82(27.1) | 94(33.6) | 1.00(ref.) | 0.03 |
| AA | CC, CT | 104(34.3) | 94(33.6)
|
1.27(0.94–1.93) | |
| AG,GG | CC | 50(16.5) | 44(15.7) | ||
| AG,GG | CC,CT | 67(22.1) | 48(17.1) | 1.83(1.08–3.13) | |
| Female lung adenocarcinoma patients | |||||
| AA | CC | 42(14.1) | 63(18.9) | 1.00(ref.) | 0.02 |
| AA | CC,CT | 65(21.9) | 57(17.1)
|
1.52(0.95–2.42) | |
| AG,GG | CC | 87(29.3) | 114(34.1) | ||
| AG,GG | CC,CT | 103(34.7) | 100(29.9) | 1.81(1.10–2.99) | |
aaOR, adjusted odds ratio; 95 %CI, 95 % confidence interval. These were estimated in a multivariate logistic regression model, containing age, years of schooling of study participants, and the smoking-related risk factors (i.e., cigarette smoking and passive smoking) identified in Table 2
bThe SNPs used in the analysis were rs6792811 (FANCD2) and rs9806604(FANCI) in males and rs6792811(FANCD2) and rs9920768(FANCI) in females